Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9966524 | 0.90 | HDAC1 (0.49) | NPSR1SMN1; SMN2GAALMNATDP1 | |
| SCHEMBL9966446 | 0.85 | HDAC1 (0.52) | IDO1HDAC1ALOX5APHDAC3HDAC7 | |
| SCHEMBL9966568 | 0.85 | HDAC1 (0.55) | IDO1HDAC1ALOX5APHDAC3HDAC7 | |
| SCHEMBL9936886 | 0.84 | IDO1 (0.48) | NPSR1MEN1KMT2ALMNAIDO1 | |
| SCHEMBL9966217 | 0.82 | HDAC1 (0.46) | NPSR1CYP2C9CYP2C19KMT2ALMNA | |
| SCHEMBL9936138 | 0.82 | HDAC1 (0.54) | IDO1HDAC1ALOX5APHDAC3HDAC7 | |
| SCHEMBL14325150 | 0.81 | HDAC1 (0.46) | IDO1HDAC1ALOX5APHDAC3HDAC7 | |
| SCHEMBL9966291 | 0.81 | GAA (0.46) | NPSR1SMN1; SMN2GAACYP2C9KMT2A | |
| SCHEMBL9966424 | 0.81 | NPSR1 (0.51) | NPSR1SMN1; SMN2GAACYP2C9CYP2C19 | |
| SCHEMBL9966491 | 0.81 | HDAC1 (0.51) | IDO1HDAC1ALOX5APHDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651930-B1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2651930-B1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-9073895-B2 | Biarylamide inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073895-B2 | Biarylamide inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073895-B2 | Biarylamide inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2651930-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012082817-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082817-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322795-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | NPSR1 716/4885SMN1; SMN2 4543/4885GAA 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.